Stock 4152 TAIWAN LIPOSOME COMPANY, LTD.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Taiwan Liposome Company, Ltd.

Equities

4152

TW0004152004

Biotechnology & Medical Research

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Taiwan Liposome Company, Ltd.

Endo Ventures Limited Executes Agreement with Taiwan Liposome Company, Ltd. to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee Pain CI
TLC BioSciences Announces Publication of Tlc599 Phase Ii Results in Arthritis Research & Therapy CI
Woods Investment Company, Ltd. completed the acquisition of Taiwan Liposome Company, Ltd. from a group of sellers. CI
Taiwan Liposome Company, Ltd.(NasdaqGM:TLC) dropped from NASDAQ Composite Index CI
Taiwan Liposome : to Voluntary Delist From Nasdaq MT
TAIWAN LIPOSOME : HC Wainwright Lowers Taiwan Liposome to Neutral From Buy, Price Target to $7.50 From $11 MT
TAIWAN LIPOSOME : Laidlaw Downgrades Taiwan Liposome to Hold From Buy MT
Woods Investment Company, Ltd. agreed to acquire Taiwan Liposome Company, Ltd. from a group of sellers for TWD 9.2 billion. CI
Taiwan Liposome Company, Ltd. and Endo International plc Enter a Commercialization Agreement for A Liposomal Product CI
TLC and Strides Pharma Science Limited Partner to Launch Liposomal Amphotericin B in India CI
Taiwan Liposome : Working With Zydus Healthcare to Provide Supply of AmphoTLC in India MT
TLC and Zydus Enter Agreement to Launch AmphoTLC™ in India CI
Taiwan Liposome : TLC Secures India's Approval For Mucormycosis Treatment AmphoTLC MT
Taiwan Liposome : Earnings Flash (TLC) TLC Posts Q1 Loss $-0.08 MT
Taiwan Liposome Company, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Taiwan Liposome Company, Ltd. announced a financing transaction CI
Taiwan Liposome Company, Ltd. Provides Clinical Trail Update CI
Taiwan Liposome Company, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Sector Update: Health Care Stocks Flat During Premarket Trading on Monday MT
Taiwan Liposome : Completes Patient Enrollment in Study of TLC599 in Patients With Osteoarthritis Knee Pain MT
TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis Pain CI
Taiwan Liposome Company, Ltd. Announces Management Changes CI
Taiwan Liposome : Reports 98% Enrollment of Phase 3 Study of Osteoarthritis Drug MT
TLC Announces Acceptance of Manuscript on Anti-COVID-19 Program CI
Taiwan Liposome Company, Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI

Chart Taiwan Liposome Company, Ltd.

Chart Taiwan Liposome Company, Ltd.
More charts

Company Profile

Taiwan Liposome Company, Ltd. is a Taiwan-based company principally engaged in the research and development and commercialization of lipid drug delivery systems. The Company is engaged in the development of special generic drugs, new formulas and new drugs using patents. The Company's therapeutic areas include pain management, eye diseases and cancer. Its anticancer medicine product named Lipo-Dox has been distributed in domestic and Asian markets.
Sector
Biotechnology & Medical Research
More about the company

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.51% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+3.22% 97.42B
ARGENX SE Stock argenx SE
+1.46% 22.2B
BIONTECH SE Stock BioNTech SE
-16.53% 21.23B
GENMAB A/S Stock Genmab A/S
-8.96% 18.33B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.33% 16.35B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.09% 15.06B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.47% 13.98B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.85% 11.66B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 4152 Stock
  4. News Taiwan Liposome Company, Ltd.
  5. Taiwan Liposome : HC Wainwright Lowers Taiwan Liposome to Neutral From Buy, Price Target to $7.50 From $11